Investigation in Progress — No Complaint Filed Yet
BG&G is actively investigating potential securities fraud claims against Protalix BioTherapeutics, Inc.. If a complaint is filed, this page will be updated. Investors are encouraged to contact us now to preserve their rights.
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Protalix BioTherapeutics, Inc. (“Protalix” or “the Company”) (NYSE: PLX). Investors who purchased Protalix securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Protalix has violated federal securities laws.
Investigation Details
On October 17, 2025, Protalix and Chiesi Global Rare Diseases, Protalix’s partner in “the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system”, issued a press release “acknowledging that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a negative opinion on the request to approve the dosing regimen of 2 mg/kg body weight infused every 4 weeks (E4W) for Elfabrio (pegunigalsidase alfa, in addition to the currently approved dosing regimen of 1 mg/kg body weight infused every 2 weeks (E2W).” Following this news, Protalix’s stock price fell $0.54 per share, or 22.5%, to close at $1.86 per share on October 17, 2025.
What’s Next?
If you are aware of any facts relating to this investigation or purchased Protalix securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660
PLX — Stock Performance
About Bronstein, Gewirtz & Grossman, LLC
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.”